U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148245) titled 'Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma' on Aug. 22.
Brief Summary: The introduction of immune checkpoint inhibitors (ICIs) for the treatment of patients with stages IIB to IV cutaneous melanoma resulted in dramatic improvements in mortality rates for this common form of cancer. With this rapid shift in treatment, significant gaps in knowledge exist regarding the impact of ICIs on patients' symptom experiences. An in-depth characterization of inter-individual differences in patients' symptom experiences will fill this knowledge gap and assist with the early detection of ICI toxicity; guide symptom manag...